X

Drug Profile

cmRNA 1210

Alternative Names: cmRNA-1210

Latest Information Update: 10 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Suzhou CureMed Biopharma Technology
Class Antineoplastics; Circular RNA; Immunotherapies
Mechanism of Action Immunostimulants; Interleukin-12 expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

31 May 2024 Preclinical trials in Solid tumours in China (Parenteral), prior to May 2024
31 May 2024 Efficacy and adverse events data from preclinical studies in solid tumours were presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024) .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com